Positive results from Phase 2 Sleep Signal Analysis for Current Major Depressive Episode (SAMDE) Study SmartNews
Positive Phase 2a Fibromyalgia Results Deliver Pain Reduction in 100% of Patients, Strengthening IP Position and Clinical Trial Strategy Life Science Investing News
Novartis receives FDA accelerated approval for Fabhalta® , the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy Pharmaceutical Investing
Notice of Knight Therapeutics' Second Quarter 2024 Results Conference Call Life Science Investing News
Rett Syndrome Patients Show Further Clinical Improvement After 20 Weeks of NTI164 Treatment Pharmaceutical Investing
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update Pharmaceutical Investing
